

# CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study

SALOMON M. STEMMER,<sup>a</sup> OFER BENJAMINOV,<sup>a</sup> GAL MEDALIA,<sup>a</sup> NOAB B. CIURARU,<sup>a</sup> MICHAEL H. SILVERMAN,<sup>b</sup> SARA BAR-YEHUDA,<sup>b</sup> SARI FISHMAN,<sup>b</sup> ZIVIT HARPAZ,<sup>b</sup> MOTTI FARSTEIN,<sup>b</sup> SHIRA COHEN,<sup>b</sup> RENANA PATOKA,<sup>b</sup> BARAK SINGER,<sup>b</sup> WILLIAM D. KERNS,<sup>b</sup> PNINA FISHMAN<sup>b</sup>

<sup>a</sup>Institute of Oncology, Department of Radiology (OB), Davidoff Center, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; <sup>b</sup>Can-Fite BioPharma Ltd., Petah-Tikva, Israel

Access the full results of this trial and read all published Clinical Trial Results at <http://clinicaltrialresults.theoncologist.com/search/results>

## AUTHOR SUMMARY

### ABSTRACT

**Background.** The A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patients with hepatocellular carcinoma (HCC). The orally active drug candidate CF102, an A<sub>3</sub>AR agonist, induces apoptosis of HCC cells via deregulation of the Wnt signaling

pathway. In this open label phase I/II trial, the safety and clinical effects of CF102 were assessed in patients with advanced unresectable HCC.

**Methods.** The primary objectives of this trial were to examine the safety and pharmacokinetic (PK) behavior of CF102 given orally (1, 5, and 25 mg BID) in 28-day cycles. Evaluation of anti-tumor effects and the utilization of A<sub>3</sub>AR as a biological predictive marker of response to CF102 were the secondary objectives.

**Results.** Eighteen patients received CF102—six at each dose level. No serious drug-related adverse events or dose-limiting toxicities were observed. CF102 demonstrated good oral bioavailability and linear PK behavior. Median overall survival in the study population, 67% of whom had received prior sorafenib, was 7.8 months, and for Child Pugh B patients (28%) it was 8.1 months. Stable disease by RECIST was observed in four patients for at least 4 months. CF102 maintained liver function over a 6-month period. A correlation between receptor overexpression levels at baseline and patients' overall survival was found. One of the patients who presented with skin nodules that were biopsy-proven to be HCC metastases prior to the trial showed complete metastasis regression during three months of treatment with CF102.

**Conclusions.** CF102 is safe and well-tolerated, showing favorable PK characteristics in Child Pugh A and B HCC patients, justifying further clinical development.

### DISCUSSION

The current study demonstrates that CF102 is safe and well tolerated, with a linear PK at the dose range used during the study. The adverse events that were observed are expected in a population of patients with advanced HCC.

### Overall survival data

| Subject number | Starting dose (mg BID) | Months from diagnosis to CF102 | Months previously on sorafenib | Entry Child-Pugh class | Survival from start of CF102 (months) |
|----------------|------------------------|--------------------------------|--------------------------------|------------------------|---------------------------------------|
| 302            | 1                      | 27                             | —                              | A                      | 8.2                                   |
| 303            | 1                      | 8                              | —                              | A                      | 27.3                                  |
| 304            | 1                      | 5                              | —                              | A                      | 7.1                                   |
| 305            | 5                      | 18                             | 8.2                            | A                      | 4.1                                   |
| 306            | 5                      | 14                             | 7.0                            | A                      | 7.1                                   |
| 307            | 5                      | 24                             | 1.4                            | A                      | 10.6                                  |
| 308            | 25                     | 14                             | 10.8                           | A                      | 8.3                                   |
| 309            | 25                     | 1                              | —                              | B                      | 8.1                                   |
| 310            | 25                     | 1                              | —                              | B                      | 7.6                                   |
| 312            | 5                      | 20                             | —                              | B                      | 10.7                                  |
| 313            | 25                     | 14                             | 3.3                            | B                      | 7.0                                   |
| 314            | 1                      | 53                             | 4.8                            | A                      | 5.6                                   |
| 315            | 5                      | 22                             | 8.0                            | A                      | 3.5                                   |
| 316            | 25                     | 78                             | 2.3                            | A                      | 12.6                                  |
| 317            | 1                      | 26                             | 5.0                            | B                      | 13.2                                  |
| 318            | 1                      | 33                             | 24.2                           | A                      | 7.0                                   |
| 319            | 5                      | 19                             | 2.6                            | A                      | 4.2                                   |
| 320            | 25                     | 19                             | 6.0                            | A                      | 8.4                                   |
| <b>Median</b>  |                        |                                | <b>All</b>                     |                        | <b>7.8</b>                            |
|                |                        |                                | <b>Sorafenib failures</b>      |                        | <b>7.0</b>                            |
|                |                        |                                | <b>Child Pugh B</b>            |                        | <b>8.1</b>                            |

ClinicalTrials.gov Identifier: NCT00790218  
Sponsor: Canfite Biopharma Ltd

Principal Investigators: Pnina Fishman, Salomon M. Stemmer  
IRB Approved: Yes

Correspondence: Pnina Fishman, Ph.D., Can-Fite BioPharma, 10 Bareket Street, P.O.Box 7537, Petach-Tikva 49170, Israel. Telephone: 972-3-9241114; Fax: 972-3-9249378; e-mail: pnina@canfite.co.il; first published online in *The Oncologist Express* on January 8, 2013. ©AlphaMed Press; the data published online to support this summary is the property of the authors. <http://dx.doi.org/10.1634/theoncologist.2012-0211>

The median OS of the 18 subjects to date is 7.8 months, with one subject continuing on CF102 as of the date of this report. These results are encouraging in light of the fact that 67% of the patient population in the current study had experienced disease progression on sorafenib and that, for these patients, CF102 treatment was second-line therapy. An additional finding was the 8.1-month median OS of the five Child-Pugh B patients. Previous experience with comparable patient populations has shown an OS for Child Pugh B patients in the range of 3.5–5.5 months [1–3]. Considering that Child Pugh B patients treated with sorafenib generally have poor outcomes due to underlying liver dysfunction, CF102 also may be considered as a drug to be developed for this patient sub-population.

CF102 had no adverse effect on routine measures of liver function over a 6-month period in 12 patients treated for at least that duration. These findings corroborate clinical CF102 data published earlier that show a protective effect on normal

liver tissue in an experimental model of liver inflammation [4] and suggest that CF102 could be used in patients with cirrhosis and/or hepatic impairment. Other A3AR agonists have likewise been found to act as anti-cancer agents and concomitantly induce liver protective effects, as well as cardioprotective, neuroprotective, and myeloprotective effects [4–7].

Previous studies have reported that A3AR is up-regulated in tumor tissues of both tumor-bearing animals and humans. High receptor expression is also mirrored in patients' peripheral blood mononuclear cells, possibly reflecting receptor levels in neoplastic tissue. An increase in A3AR expression levels was also found during colorectal tumor progression, suggesting it may be possible to utilize the receptor as a biological follow-up marker [8, 9]. Further studies will be required to evaluate these possibilities. *The Oncologist* 2013;18:25–26

#### DISCLOSURES

Author disclosures available online.

#### REFERENCES

1. Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. *The Oncologist* 2009;14:70–76.
2. Pinter M, Sieghart W, Huckle F et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. *Aliment Pharmacol Ther* 2011;34:949–959.
3. Hollebecque A, Cattani S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. *Aliment Pharmacol Ther* 2011;34:1193–1201.
4. Cohen S, Stemmer SM, Zozulya G et al. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. *J Cell Physiol* 2011;226:2438–2447.
5. Fishman P, Bar-Yehuda S, Barer F et al. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. *Exp Cell Res* 2001;269:230–236.
6. Xu Z, Jang Y, Mueller RA et al. IB-MECA and cardioprotection. *Cardiovasc Drug Rev* 2006;24:227–238.
7. Chen GJ, Harvey BK, Shen H et al. Activation of A3 adenosine receptors reduces ischemic brain injury in rodents. *J Neurosci Res* 2006;84:1848–1855.
8. Madi L, Ochaion A, Rath-Wolfson L et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. *Clin Cancer Res* 2004;10:4472–4479.
9. Gessi S, Cattabriga E, Avitabile A et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. *Clin Cancer Res* 2004;10:5895–5901.